A new recombinant single chain trispecific antibody recruits T lymphocytes to kill CEA (Carcinoma Embryonic Antigen) positive tumor cells in vitro efficiently

Journal of Biochemistry

Volumn 135, Issue 4, 2004, Pages 555-565

  Wang, Xiang Bin ^a   Zhao, Bao Feng ^b   Zhao, Qi ^a   Piao, Jin Hua ^a   Liu, Jing ^a   Lin, Qing ^a   Huang, Hua Liang ^a  

^a INSTITUTE OF GENETICS AND DEVELOPMENTAL BIOLOGY   (China)

^b LANZHOU UNIVERSITY   (China)

Author keywords

CD28; CD3; CEA; Single chain trispecific antibody

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CD28 ANTIGEN; CD3 ANTIGEN; HUMAN SERUM ALBUMIN; IMMUNOGLOBULIN G; INTERLEUKIN 2; LIPOCORTIN 4; MONOCLONAL ANTIBODY; POLYPEPTIDE; PROPIDIUM IODIDE; RECOMBINANT ANTIBODY;

ANTIBODY SPECIFICITY; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CANCER IMMUNOTHERAPY; CELL KILLING; CHROMATOGRAPHY; CONTROLLED STUDY; CYTOLYSIS; EFFECTOR CELL; ESCHERICHIA COLI; HUMAN; HUMAN CELL; LOW TEMPERATURE; MICROPHOTOGRAPHY; MOLECULAR WEIGHT; PERIPHERAL BLOOD MONONUCLEAR CELL; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TARGET CELL; TUMOR CELL;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD28; ANTIGENS, CD3; APOPTOSIS; CARCINOEMBRYONIC ANTIGEN; CELL LINE, TUMOR; CHROMATOGRAPHY, ION EXCHANGE; COCULTURE TECHNIQUES; CYTOTOXICITY, IMMUNOLOGIC; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; FLOW CYTOMETRY; GENE EXPRESSION; GENETIC VECTORS; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULIN FRAGMENTS; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN VARIABLE REGION; JURKAT CELLS; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; NECROSIS; POLYMERASE CHAIN REACTION; RECOMBINANT FUSION PROTEINS; SERUM ALBUMIN; T-LYMPHOCYTES;

ESCHERICHIA COLI;

EID: 2442696260     PISSN: 0021924X     EISSN: None     Source Type: Journal    
DOI: 10.1093/jb/mvh065     Document Type: Article

References (62)

1. Baxter, A.G. and Hodgkin, P.D. (2002) Activation rules: the two-signal theories of immune activation. Nat. Rev. Immunol. 2, 439-446
2. Bernard, A., Lamy, and Alberti, I. (2002) The two-signal model of T-cell activation after 30 years. Transplantation 73, S31-35
3. Tang, Q., Smith, J.A., Szot, G.L., Zhou, P., Alegre, M.L., Henriksen, K.J., Thompson, C.B., and Bluestone, J.A. (2003) CD28/B7 regulation of anti-CD3-mediated immunosuppression in vivo. J. Immunol. 170, 1510-1516
4. Van Parijs, L., Ibraghimov, A., and Abbas, A.K. (1996) The roles of costimulation and Fas in T cell apoptosis and peripheral tolerance. Immunity 4, 321-328
5. Salih, H.R., and Nussler, V. (2001) Commentary: Immune escape versus tumor tolerance: how do tumors evade immune surveillance? Eur. J. Med. Res. 6, 323-332
6. Foss, F.M. (2002) Immunologic mechanisms of antitumor activity. Semin. Oncol. 29, 5-11
7. Withoff, S., Helfrich, W., de Leij, L.F., and Molema, G. (2001) Bi-specific antibody therapy for the treatment of cancer. Curr. Opin. Mol. Ther. 3, 53-62
8. Kudo, T., Suzuki, M., Katayose, Y., Shinoda, M., Sakurai, N., Kodama, H., Ichiyama, M., Takemura, S., Yoshida, H., Saeki, H., Saijyo, S., Takahashi, J., Tominaga, T., and Matsuno, S. (1999) Specific targeting immunotherapy of cancer with bispecific antibodies. Tohoku J. Exp. Med. 188, 275-288
9. Bauer, S., Renner, C., Juwana, J.P., Held, G., Ohnesorge, S., Gerlach, K., and Pfreundschuh, M. (1999) Immunotherapy of human tumors with T-cell-activating bispecific antibodies: stimulation of cytotoxic pathways in vivo. Cancer Res. 59, 1961-1965
10. Manzke, O., Tesch, H., Lorenzen, J., Diehl, V., and Bohlen, H. (2001) Locoregional treatment of low-grade B-cell lymphoma with CD3xCD19 bispecific antibodies and CD28 costimulation. II. Assessment of cellular immune responses. Int. J. Cancer 91, 516-522
11. Manzke, O., Tesch, H., Borchmann, P., Wolf, J., Lackner, K., Gossmann, A., Diehl, V., and Bohlen, H. (2001) Locoregional treatment of low-grade B-cell lymphoma with CD3xCD19 bispecific antibodies and CD28 costimulation. I. Clinical phase I evaluation. Int. J. Cancer 91, 508-515
12. Cochlovius, B., Kipriyanov, S.M., Stassar, M.J., Schuhmacher, J., Benner, A., Moldenhauer, G., and Little, M. (2000) Cure of Burkitt's lymphoma in severe combined immunodeficiency mice by T cells, tetravalent CD3 (CD19 tandem diabody, and CD28 costimulation. Cancer Res. 60, 4336-4341
13. Kodama, H., Suzuki, M., Katayose, Y., Shinoda, M., Sakurai, N., Takemura, S., Yoshida, H., Saeki, H., Asano, R., Ichiyama, M., Imai, K., Hinoda, Y., Matsuno, S., and Kudo, T. (2002) Specific and effective targeting cancer immunotherapy with a combination of three bispecific antibodies. Immunol. Lett. 81, 99-106
14. Holliger, P., Manzke, O., Span, M., Hawkins, R., Fleischmann, B., Qinghua, L., Wolf, J., Diehl, V., Cochet, O., Winter, G., and Bohlen, H. (1999) Carcinoembryonic antigen (CEA)-specific T-cell activation in colon carcinoma induced by anti-CD3 (anti-CEA bispecific diabodies and B7 (anti-CEA bispecific fusion proteins. Cancer Res. 59, 2909-2916
15. Jung, G., Brandl, M., Eisner, W., Fraunberger, P., Reifenberger, G., Schlegel, U., Wiestler, O.D., Reulen, H.J., and Wilmanns, W. (2001) Local immunotherapy of glioma patients with a combination of 2 bispecific antibody fragments and resting autologous lymphocytes: evidence for in situ t-cell activation and therapeutic efficacy. Int. J. Cancer 91, 225-230
16. Daniel, P.T., Kroidl, A., Kopp, J., Sturm, I., Moldenhauer, G., Dorken, B., and Pezzutto, A. (1998) Immunotherapy of B-cell lymphoma with CD3 × 19 bispecific antibodies: costimulation via CD28 prevents "veto" apoptosis of antibody-targeted cytotoxic T cells. Blood 92, 4750-4757
17. Loffler, A., Gruen, M., Wuchter, C., Schriever, F., Kufer, P., Dreier, T., Hanakam, F., Baeuerle, P.A., Bommert, K., Karawajew, L., Dorken, B., and Bargou, R.C. (2003) Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19/anti-CD3 single-chain antibody construct. Leukemia 17, 900-909
18. Dreier, T., Baeuerle, P.A., Fichtner, I., Grun, M., Schlereth, B., Lorenczewski, G., Kufer, P., Lutterbuse, R., Riethmuller, G., Gjorstrup, P., and Bargou, R.C. (2003) T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3-bispecific single-chain antibody construct. J. Immunol. 170, 4397-4402
19. Dreier, T., Lorenczewski, G., Brandl, C., Hoffmann, P., Syring, U., Hanakam, F., Kufer, P., Riethmuller, G., Bargou, R., and Baeuerle, P.A. (2002) Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody. Int. J. Cancer 100, 690-697
20. Loffler, A., Kufer, P., Lutterbuse, R., Zettl, F., Daniel, P.T., Schwenkenbecher, J.M., Riethmuller, G., Dorken, B., and Bargou, R.C. (2000) A recombinant bispecific single-chain antibody, CD19 × CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood 95, 2098-2103
21. Wong, W.M., Vakis, S.A., Ayre, K.R., Ellwood, C.N., Howell, W.M., Tutt, A.L., Cawley, M.I., and Smith, J.L. (2000) Rheumatoid arthritis T cells produce Th1 cytokines in response to stimulation with a novel trispecific antibody directed against CD2, CD3, and CD28. Scand J. Rheumatol. 29, 282-287
22. Jung, G., Freimann, U., Von Marschall, Z., Reisfeld, R.A., and Wilmanns, W. (1991) Target cell-induced T cell activation with bi- and trispecific antibody fragments. Eur. J. Immunol. 21, 2431-2435
23. Tutt, A., Stevenson, G.T., and Glennie, M.J. (1991) Trispecific F(ab′)3 derivatives that use cooperative signaling via the TCR/CD3 complex and CD2 to activate and redirect resting cytotoxic T cells. J. Immunol. 147, 60-69
24. French, R.R. (1998) Production of bispecific and trispecific F(ab)2 and F(ab)3 antibody derivatives. Methods Mol. Biol. 80, 121-134
25. Kortt, A.A., Dolezal, O., Power, B.E., and Hudson, P.J. (2001) Dimeric and trimeric antibodies: high avidity scFvs for cancer targeting. Biomol. Eng. 18, 95-108
26. Dolezal, O., Pearce, L.A., Lawrence, L.J., McCoy, A.J., Hudson, P.J., and Kortt, A.A. (2000) ScFv multimers of the anti-neuraminidase antibody NC10: shortening of the linker in singlechain Fv fragment assembled in V(L) to V(H) orientation drives the formation of dimers, trimers, tetramers and higher molecular mass multimers. Protein Eng. 13, 565-574
27. Atwell, J.L., Breheney, K.A., Lawrence, L.J., McCoy, A.J., Kortt, A.A., and Hudson, P.J. (1999) scFv multimers of the anti-neuraminidase antibody NC10: length of the linker between VH and VL domains dictates precisely the transition between diabodies and triabodies. Protein Eng. 12, 597-604
28. Willems, A., Leoen, J., Schoonooghe, S., Grooten, J., and Mertens, N. (2003) Optimizing expression and purification from cell culture medium of trispecific recombinant antibody derivatives. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 786, 161-176
29. Schoonjans, R., Willems, A., Schoonooghe, S., Leoen, J., Grooten, J., and Mertens, N. (2001) A new model for intermediate molecular weight recombinant bispecific and trispecific antibodies by efficient heterodimerization of single chain variable domains through fusion to a Fab-chain. Biomol. Eng. 17, 193-202
30. Schoonjans, R., Willems, A., Schoonooghe, S., Fiers, W., Grooten, J., and Mertens, N. (2000) Fab chains as an efficient heterodimerization scaffold for the production of recombinant bispecific and trispecific antibody derivatives. J. Immunol. 165, 7050-7057
31. Somasundaram, C., Sundarapandiyan, K., Keler, T., Deo, Y.M., and Graziano, R.F. (1999) Development of a trispecific antibody conjugate that directs two distinct tumor-associated antigens to CD64 on myeloid effector cells. Hum. Antibodies 9, 47-54
32. Min Fang, R.Z., Zhi Yang, Zhong Zhang, Hua Li, Xue-Tao Zhang, Qing Lin, and Hua-Liang Huang. (2004) Characterization of an anti-human ovarian carcinoma_antihuman CD3 bispecific single-chain antibody with an albumin-original interlinker. Gynecol. Oncol. in press
33. Min Fang, X.J., Zhi Yang, Cong-Xiao Yu, Cheng-Chang Yin, Hua Li, Rui Zhao, Zhang-Zhang, Qin-Lin, Hua-Liang Huang. (2003) Effect of inter-linker on the activaty of single chain bispecific antibody. Chines Sci. Bull. 48, 1912-1918
34. Fang M, Z.R., Li H, Jiang X, Yin C, Lin Q, Huang H. (2002) Construction and expression of an anti-human ovarian carcinoma-anti-human CD3 bispecific single-chain antibody and its refolding studies. High Technol. Lett. 12, 47-50
35. Cheng, J., Wang, X., Zhang, Z., and Huang, H. (2002) Construction and expression of a reshaped VH domain against human CD28 molecules. Prep. Biochem. Biotechnol. 32, 239-251
36. Cheng, J.L., Wang, X.B., Zhang, Z., Liu, J., Yao, X.S., and Huang, H.L. (2002) A method for constructing reshaping single-domain antibody. Yi Chuan Xue Bao 29, 189-195
37. Zhang, Z., Li, Z.H., Wang, F., Fang, M., Yin, C.C., Zhou, Z.Y., Lin, Q., and Huang, H.L. (2002) Overexpression of DsbC and DsbG markedly improves soluble and functional expression of single-chain Fv antibodies in Escherichia coli. Protein Exp. Purif 26, 218-228
38. Rosenberg, A.H., Lade, B.N., Chui, D.S., Lin, S.W., Dunn, J.J., and Studier, F.W. (1987) Vectors for selective expression of cloned DNAs by T7 RNA polymerase. Gene 56, 125-135
39. Studier, F.W., Rosenberg, A.H., Dunn, J.J., and Dubendorff, J.W. (1990) Use of T7 RNA polymerase to direct expression of cloned genes. Methods Enzymol. 185, 60-89
40. Koga, H., Kanda, H., Nakashima, M., Watanabe, Y., Endo, K., and Watanabe, T. (1990) Mouse-human chimeric monoclonal antibody to carcinoembryonic antigen (CEA): in vitro and in vivo activities. Hybridoma 9, 43-56
41. Borst, J., Prendiville, M.A., and Terhorst, C. (1983) The T3 complex on human thymus-derived lymphocytes contains two different subunits of 20 kDa. Eur J. Immunol. 13, 576-580
42. Schneider, U., Schwenk, H.U., and Bornkamm, G. (1977) Characterization of EBV-genome negative "null" and "T" cell lines derived from children with acute lymphoblastic leukemia and leukemic transformed non-Hodgkin lymphoma. Int. J. Cancer 19, 621-626
43. Weiss, A., and Stobo, J.D. (1984) Requirement for the coexpression of T3 and the T cell antigen receptor on a malignant human T cell line. J. Exp. Med. 160, 1284-1299
44. Weiss, A., Manger, B., and Imboden, J. (1986) Synergy between the T3/antigen receptor complex and Tp44 in the activation of human T cells. J. Immunol. 137, 819-825
45. Leibovitz, A., Stinson, J.C., McCombs, W.B., 3rd, McCoy, C.E., Mazur, K.C., and Mabry, N.D. (1976) Classification of human colorectal adenocarcinoma cell lines. Cancer Res. 36, 4562-4569
46. Ganjei, P., Nadji, M., Albores-Saavedra, J., and Morales, A.R. (1988) Histologic markers in primary and metastatic tumors of the liver. Cancer 62, 1994-1998
47. Kammerer, U., Thanner, F., Kapp, M., Dietl, J., and Sutterlin, M. (2003) Expression of tumor markers on breast and ovarian cancer cell lines. Anticancer Res. 23, 1051-1055
48. Dorvillius, M., Garambois, V., Pourquier, D., Gutowski, M., Rouanet, P., Mani, J.C., Pugniere, M., Hynes, N.E., and Pelegrin, A. (2002) Targeting of human breast cancer by a bispecific antibody directed against two tumour-associated antigens: ErbB-2 and carcinoembryonic antigen. Tumour Biol. 23, 337-347
49. Tomita, Y., Arakawa, F., Hirose, Y., Liao, S., Khare, P.D., Kuroki, M., Yamamoto, T., and Ariyoshi, A. (2000) Carcinoma-associated antigens MK-1 and CEA in urological cancers. Anticancer Res. 20, 793-797
50. Osaki, T., Tanio, Y., Tachibana, I., Hosoe, S., Kumagai, T., Kawase, I., Oikawa, S., and Kishimoto, T. (1994) Gene therapy for carcinoembryonic antigen-producing human lung cancer cells by cell type-specific expression of herpes simplex virus thymidine kinase gene. Cancer Res. 54, 5258-5261
51. Kuo, W.R., Tsai, S.M., Jong, S.B., and Juan, K.H. (1996) Significance of tumour markers in nasopharyngeal carcinoma. J. Otolaryngol. 25, 32-36
52. Xia, Z., Pu, P., and Huang, Q. (2001) [Effect of transfected Cx43 gene on the gap junction intercellular communication and the human glioma cells proliferation]. Zhonghua Zhong Liu Za Zhi 23, 465-468
53. Sambrook, J., and Russell, D.W. (2001) Molecular Cloning: a Laboratory Manual, 3rd ed. 3 vols., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
54. Ausubel, F.M. (1999) Short protocols in Molecular Biology: a Compendium of Methods from Current Protocols in Molecular Biology, 4th ed., Wiley, New York
55. Darbre, A. (1986) Practical Protein Chemistry: a Handbook. analytical methods., Wiley, Chichester [Sussex]; New York
56. Clark, W.R. (1991) The Experimental Foundations of Modern Immunology, 4th ed., Wiley, New York; Chichester
57. Vermes, I., Haanen, C., Steffens-Nakken, H., and Reutelingsperger, C. (1995) A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J. Immunol. Methods 184, 39-51
58. Kipriyanov, S.M., Moldenhauer, G., Braunagel, M., Reusch, U., Cochlovius, B., Le Gall, F., Kouprianova, O.A., Von der Lieth, C.W., and Little, M. (2003) Effect of domain order on the activity of bacterially produced bispecific single-chain Fv antibodies. J. Mol. Biol. 330, 99-111
59. Martin, S.J., Rentelingsperger, C.P., McGahon, A.J., Rader, J.A., van Schie, R.C., LaFace, D.M., and Green, D.R. (1995) Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. J. Exp. Med. 182, 1545-1556
60. Koopman, G., Rentelingsperger, C.P., Knijten, G.A., Keehnen, R.M., Pals, S.T., and van Oers, M.H. (1994) Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood 84, 1415-1420
61. Lowin, B., Hahne, M., Mattmann, C., and Tschopp, J. (1994) Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways. Nature 370, 650-652
62. Kagi, D., Vignaux, F., Ledermann, B., Burki, K., Depraetere, V., Nagata, S., Hengartner, H., and Golstein, P. (1994) Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science 265, 528-530